An appraisal of the growth potential of the pharmaceutical industry and its application to security values, 1959 by Chappelle, John Henry (Author)
AN APPRAISAL OP THE GROWTH POTENTIAL OP
THE PHARMACEUTICAL INDUSTRY AND ITS
APPLICATION TO SECURITY VALUES
A THESIS
SUBMITTED TO THE PACULTY OP ATLANTA UNIVERSITY IN
PARTIAL PULPILLMENT OP THE REQUIREMENTS POR THE
DEGREE OP MASTER OP BUSINESS ADMINISTRATION
BY
JOHN HENRY CHAPPELLE











II. THE PHARMACEUTICAL INDUSTRY . , . .
Historical Background ••






III. SECURITY VALUES WITHIN THE INDUSTRY
Industry Growth Prospects
Earnings Trends of the Industry ......
Industry Profits •
Drug Securities ......
Performance of Securities . .
IV. LONG TERM GROWTH PROSPECTS OP THE INDUSTRY. . .
Population Trends and Longevity
Expansion of Poreign Markets
Anti-Trust Action
Miscellaneous Growth Areas ........
Industry Projections



























1. Output of Leading Antibiotics and Per Cent of
Total Output - 19^9 1956 6
2. The Effect on Sales and Earnings Within Two Years
After the Introduction of a New Product. .... 26
3. Net Income for Three Leading Drug Producers for
the Ten Year Period 19^1-9 ” 1958 • 3^
Comparative Net Income of Eleven Leading Drug
Companies and 378 Industrial Companies Combined. 37
5. Average Operating Income As a Percentage of Not
Sales of Some Selected Industries For the Years
1950 - 1957 * 38
6. Percentage of Net Profits Before Federal Taxes
To Assets of Drug Manufacturers Compared With
All Other Manufacturing Industries Ip.
7. Stock Statistics of Some Leading Drug Producers. 1|.6





Problem*—The problem of this study is to evaluate avail¬
able information on the pharmaceutical Industry and to present
evidence to support the hypothesis set forth* The hypothesis
set forth in this study is that the pharmaceutical industry is
a growth industry having tremendous potential for expansion
and that, concomitantly, drug stocks appreciate in value mak¬
ing them superior to many other Industry stocks for long-run
Investment purposes*^
Scope*—The scope of this study is, of necessity, of a
somewhat limited nature due to the very recent emergence of
the drug Industry from a state of virtual non-existence, less
than twenty years ago, to the present state of an industry en¬
joying sales of about fl>700,000,000 in 1957»^ The pharmaceu¬
tical Industry, then lacks the long, and not always glorious,
past of the oil, steel, or the railroad Industries and does
not have the wealth of material that has been written coneern-
There seems to be no clear out distinction between the
terms drugs and pharmaceuticals * Currently members of the pro¬
fession which dispenses prescription products are engaged in a
controversy over whether they should be known officially as
druggists or pharmacists. In this study the common practice
of using the terms interchangeably will be followed.
2
From a speech by Ernest H. Volwiler, President of General
Manager, Abbott Laboratories, presented before the New York So¬
ciety of Security Analysts, New York City, January l6, 1959* P* 2.
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Ing 3ome of the other industries.
This study will be concerned with the period following
1914.3 or what is called the beginning of the "wonder drug" era.
The major emphasis will cover a period of approximately ten
years.
Source of materials,—There is a noticeable lack of pub¬
lished material, in book form, on the pharmaceutical Industry.
Moat of the information contained in this study was obtained
through direct correspondence with the leading drug manufac^
turers, security analysts, and agencies of the Federal Govern¬
ment, especially the Federal Trade Commission whose two-year
study, "Economic Report on Antibiotics Manufacture", is prob¬
ably the most comprehensive study that has been made of the
industry to date. In addition, periodicals and the available
books on the subject were consulted.
Significance of study,—With the current upturn in eco¬
nomic activity and the attendant interest that has been gener¬
ated in the stock market, a great number of persons have begun,
or have become interested in beginning, a program of investment
in common stock. The reasons for this public interest in stocks
are many and varied but it is believed that a large number are
interested because of the prevailing belief that common stocks
are a hedge against inflation.
If we are to assume that the above reasoning represents
the thinking of a substantial number of individuals, then these
Individuals are interested in growth stocks, stocks that appro-
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data In valua over a period of time, and which will keep
pace with the cost of living increases and other inflation¬
ary movements. In addition, Americana are steadily buying
more drugs and sundries. Pharmaceutical sales have quadrupled
in the last ten years, and new prescription specialties are
appearing at the rate of foior hundred a year.^ These tenden¬
cies, in part, form the basis for the case that the writer is
attempting to construct for the potential growth of the in¬
dustry .
This study should be of interest to those persons who have
a desire for information concerning long-term prospects for val
ue appreciation and who wish some basis for comparing the phar¬
maceutical industry with some other industries.
This study is also Intended to provide some information,
which has not been widely disseminated, about the Industry con¬
cerning marketing pricing policies, and profit margins.





Pharmacy and the pharmaceutical Industry are the result
of progressive growth over the past one hundred years. The
development of the pharmaceutical Industry Is the transition
from the apothecary shops of a century ago to today’s produc¬
tion of drugs on a massive scale, according to accurate stand¬
ards, with rapid distribution, on an extensive basis. Just as
medicine and pharmacy divided Into separate professions during
the 1700's, so pharmacy has become more specialized during the
past century. The pharmaceutical Industry could perhaps be
called the manufacturing branch of pharmacy.
The beginning of the Industry In America goes back to the
American Indian. The American aborlgenes knew and used Indige¬
nous medicinal plants and each Indian tribe had Its combination
of prlest-prophet-physlclan-pharmaelst.^ Although the prac¬
tices of the medicine men were somewhat crude It Is now realized
that some of them had a good basis In scientific truth.
During the exploration of the North American continent
In the sixteenth century by the Spanish and French, successive
explorers took note of the medicinal plants growing In America.
1
John G. Glover and William B. Cornell, The Development




Scientists accompanying the expeditions recorded and helped to
popularize New World drugs in Europe. The first trained phar¬
macist in America came with the expedition of Carter in 1535.^
As colonies were established along the Atlantic seaboard,
the practice of medicine and pharmacy seemed largely to follow
Indian lore. In these colonies, however, many physicians and
apothecaries turned their attention to producing their own me¬
dicinal substances. The earliest apothecary shop was opened
2
in Boston in 181^.6.
During the middle of the eighteenth century, proposals
were made for the separation of medicine and pharmacy. An a-
pothecary was appointed on the initiative of Benjamin Franklin
in 1752 to serve at Pennsylvania Hospital in Philadelphia. It
is said that the suggestion that physicians write prescriptions
to be prepared by apothecaries at first did not meet with favor
as many physicians preferred to dispense, but as prominent medi¬
cal men gave their support, the idea gained in favor and aided
in the establishment of pharmacy as a separate profession.^
Uniformity in pharmaceutical practice gradually developed
as the American colonies became more populous and as travel in¬
creased. Later pharmacy began to change from the European types.
Just as the people did, and became more and more individualistic





perhaps, of special Interest to note that during the Revolu¬
tionary period In this country the pharmaceutical activities
were sufficiently well organized to establish a pharmaceutical
service In the Army and In the hospitals under a directing of-
1
fleer known as the Apothecary General* ,
The American Revolution provided the Impetus for the colo¬
nists to manufacture medical products on a large scale. An army
hospital established by the Continental Congress was supplied
with medicines by wholesale druggists. Then, as the result of
a plan for a central supply of drugs for the Continental Army,
a general laboratory to prepare medicines was established at
P
Carlisle, Pennsylvania. Certain apothecaries and wholesalers
soon followed this example. They found It profitable to pre¬
pare medicinal formulae In large quantltltes and to supply them
to other apothecary shops. Thus developed the first pharmaceu¬
tical manufacturers.^
With the Impetus provided by the Revolutionary War the
pharmaceutical houses along the Eastern Seaboard In the early
part of the nineteenth century. New discoveries In manufac¬
turing processes In the nineteenth century brought changes to
the Industry* For pulverizing purposes, for example, the mortar
1
John C. Krantz, Jr., Fighting Disease With Drugs (New York,
1931), P. kk-
2
Francis C. Brown, The Pharmaceutical Industry (Bloomfield,




and pestl# were replaced by grinding mills and the first ma¬
chine for the compression of tablets was constructed in 16614..^
During the Civil War pharmacy moved from a local level
to a national level when medical supplies had to be available
for troops on widely scattered fronts. The same necessity also
started a movement toward standardization of products. With
the advent of more and more manufacturers of medicinal prepara¬
tions, the need for product standardization became apparent.
The Lltitz (Pennsylvania) Pharmacopoeia, a military formulary
published in 1778» attempted to set the standard for reliable
pharmaceutical work but the first ”offielal” United States
Pharmacopoeia appeared in l820 and had as its purpose ”to regu¬
late the preparation of medicines.
The golden age of pharmaceutical research can be said to
have begun with the work of Paul Ehrlich, the German bacteriolo¬
gist, whose careful testing of hundreds of arsenic compounds led
to the development of Compound 606, Salvarsan, for the treatment
of syphilis.^ Ehrlich, known as the father of modern chemother¬
apy, startled and encouraged the world in I9IO with his discov¬
ery and his methodical testing of over 600 arsenical derivatives
was the genesis of modern research technique and methodology.^
^Ibid., p. 10.
2
John G. Glover and William B. Cornell, op cit., p. 1^62.
3
Health News Institute, Facts About Pharmacy and Pharmaceu¬
ticals (New York, 1958), p. 11.
k
John G. Krantz, Jr., op. cit., p. l53*
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Th.e Germans, in fact, completely dominated the field of phar¬
maceutical chemicals up until World War I was based largely on
European research.^
American organic chemical and pharmaceutical research
companies began to synthesize many of the organic medicinals
that were formerly procurable only from Europe. The post
World War I period generated the organized reseach by many com¬
panies that was the real genesis of today's pharmaceutical in¬
dustry, as we know it, and the movement of the industry into
what is sometimes called the ’’wonder drug" era. The six years
of World War II marked by far the greatest medical progress of
any comparable period in history. Much of this progress was
the culmination of work started in previous years. Among the
important developments were penicillin, blood plasma and its
2
factions, and new drugs for control of tropical disease. More
significant than the specific products, however, is the fact
that scientific, medical, industrial and governmental resoxu’ces
were mobilized to a,ttack the problems of supplying medicine for
a global war. This mobilization raised the medical research
and development effort in this country to a new and permanently
higher plane.
The "wonder drug" era began in 1943* with the production
of penicillin. This first miracle antibiotic was followed by
a flood of new products - streptomycin, sulfas, vitamins, hor-
^Francls C. Brown, op. eit., p. 11.
2
Health News Institute, op. clt., p. 12.
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monea, antihistamines, broad range antibiotics and tranquiliz¬
ers. This era advanced the industry into the billion dollar
classification and changed the pharmaceutical industry from a
small, quiet, orderly affair to a fast-moving, noisy, fiercely
competitive operation. These changes have become evident at
many levels and in the following section these changes as ap¬
plied to today's industry will bo examined. In examining the
Industry, the major emphasis will be placed on the manufacture
of antibiotics because they are the "money” drugs and the ones
which have the dramatic and sometimes spectacular effect on
earnings.
Since the war, manufacturers of pharmaceuticals have in¬
creased their Investments in extremely complicated and costly
scientific research and development programs. Major results of
these programs have been: (1) the development of new antibio¬
tics of a potency undreamed of only a few years ago; (2) anti¬
histamines to control allergies; (3) the isolation and synthesis
of steriod hormones, like cortisone, which have added to know¬
ledge concerning the chemical control of body processes; (i;.)
the discovery of a group of drugs, both synthetic and natural,
known as the tranquilizers, which have helpted to revolution¬
ize the treatment of the mentaly ill as well as to bring relief
to the distraught; and (5) vaccines against dread diseases like
polio.
In analyzing or projecting the earnings potential and the
long-run prospects of an industry, it becomes necessary to know
something of its operations. The following section will deal
10
primarily with production, research and development and market¬
ing, along with other factors affecting the industry which have
some bearing on its earnings.
THE PHARMACEUTICAL INDUSTRY TODAY
General Survey of the Industry
The United States Department of Commerce Census of Manu¬
facturers for reported 1,163 manufacturers of pharmaceu¬
tical preparations in the United States, 93 of biological pro¬
ducts, and 115 of medicinal chemicals. Pharmaceutical manufac¬
turers employed 76,555 persons, biological products manufacturers
employed 3»965 workers and medicinal chemical manufacturers
employed ll,5i^-l persons.^
There are some 200 companies of appreciable size manufac¬
turing drugs in the United States today and the magnitude of
the growth of the Industry can be visualized by observing the
fact that in 1939 the ethical drug sales of the industry amount¬
ed to about ^150,000,000. In 1957, the sales were about
$1,700,000,000, an Increase of about 1100 per cent in 17 years.
For the most part, pharmaceutical plants are concentrated
in the more heavily populated East and Middle Wept, where prox¬
imity to skilled labor and supplies of raw materials renders
their operation most convenient. The states of New York, Penn-
-
United States Department of Commerce, United States Census
of Manufacturers (Washington, 195^1-), II, 28C-l5»
2
Ernest H. Volwiler, op. cit., p. 2.
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aylvanla, New Jersey, Michigan, Illinois and Indiana are the
principal centers of pharmaceutical manufacture. Some phar¬
maceutical chemical manufacturing is carried on In the South,
Southwest, and Par West, but it is relatively small by com¬
parison with the Eastern and Mlddlewestern states mentioned
above.^
The pharmaceutical manufacturers about which we are con¬
cerned in this study are the manufacturers of the antibioticsJ
narrow-spectrum, meditun-spectrxim, and broad-spectrum. There
are some twelve producers of antibiotics who produced approx¬
imately 3*100,000 pounds of antibiotics in 1956 as compared
with slightly more than 2i4.0,000 pounds In 19i|-8» or about a
2
thirteenfold increase in nine years.
There are two important associations of American manufac¬
turers of medical specialties and standard products, the Ameri¬
can Drug Manufacturers' Association (ADMA) and the American
Pharmaceutical Manufacturers Association (APMA). The former
comprises between 6o and 70 per cent of the larger firms in
the industry; the latter has some 270 members, including the
majority of the members of the American Drug Mantifacturers
Association.^ The American Drug Manufacturers Association,
1
Francis C. Brown, op« eit., p. I3.
2
Federal Trade Commission, Economic Report on Antibiotics
Manufacture (Washington, 1958), p. 72. This report will here¬
after be referred to as Federal Trade Commission Rftport.
3
Pharmaceutical Productivity Team Report, Pharmaceuticals
(London, 1951), p. 7* This report will hereafter be referred
to as Productivity Team Report.
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founded in 1912, la comprised of manufacturers of ethical
pharmaceuticals, chemicals, biological or other products In¬
tended for use by the medical and allied professions In ’’the
cure, alleviation, mitigation or prevention of disease,”^ It
assists scientific and governmental agencies In the development
of standards, encourages medical research, cooperates with regu¬
latory agencies, and disseminates Information on governmental
policies. The American Pharmaceutical Manufacturers Associa¬
tion, founded In I909, b^ss as Its active members manufacturers
of drugs sold on prescription. Its associate members are sup¬
pliers of goods and services to the industry. Its meetings
serve as an industry forum for the exchange of research Infor¬
mation, maintenance of drug standards, and the study of market-
Ing, legislation and brand registration.
The search for new Investment opportunities and greater
diversification has led to the formation of holding companies
and large corporate structures in the phasrmaceutical industry.
This is perhaps exemplified by the American Home Products Cor¬
poration, Sterling Drug Incorporated, and Vick Chemical Com¬
pany. These are, however, by no means the only ones which are
widely diversified but are intended as representations of what
appears to be a growing trend within the Industry.
The objective of the holding company usually seems to in¬
clude the acquisition of producers of prescription products,
^Health News Institute, op. clt., p. 113.
^Ibld.. p. llij-.
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producers of prescription products, producers of cosmetics
and perfumes or of toilet articles, producers of household
remedies, and producers of proprietary medicines* Sometimes,
however, the aqulsitlons are not producers at all but distri¬
bution and packaging facilities*
The extent and magnitude of the diversification within
some of the ’’giants” of the industry can be obtained from the
fact that American Home Products Corporation has (1) a Pharma¬
ceutical, Biological and Nutritional Division; (2) a Household
Products Division; (3) a Packaged Drug and Cosmetic Division;
and (l^.) a Food Division* The four main divisions contain sev¬
en main corporations plus a host of smaller subsidiaries* They
manufacture a multitude of products ranging from chili con earns,
Sani-Plush and Griffin shoe polish to the finest of medicinal
chemicals and the most esoteric of the wonder drugs*^
Sterling Drug, Inc*, has five divisions, ten domestic sub¬
divisions and thirteen foreign subsidiaries* This very diversi¬
fied structure produces a variety of products which embrace a
range from antibiotics (Neo-Synephrlne), to proprietary products
(Bayer Aspirin), to laundry products (Energine and Fleecy White
Bleach)* Likewise the Vick Chemical Company and its three di¬
visions, Vick Products Division, Vick Manufacturing Division
and Vick International Division, are composed of some ten sepa-
^Francia C* Brown, op* clt., p* 20*
2
Ibid*
rate companies which manufacture a line of merchandise extend¬
ing from plastic containers to surgical items.^
Antibiotic Production
Certain strains of micro-organisms are able to kill or re¬
press the growth of other micro-organisms which cause diseases.
Science and industry have exploited this characteristic of these
strains of micro-organisms and the result is today’s antibiotic
drugs*
Antibiotics are produced principally for fermentation.
Louis Pasteur, through his work with microbes and fermentation,.
had suggested that human diseases could be cured by marshaling
microbe against microbe and in I9OI Rudolph Emmerich and Oscar
Law,, of the University of Munich, isolated pyocyanase, a power-
2
ful germ killer, from microbes* This, then, was the world's
first antibiotic but since it was ahead of its time in that
quality controls were nonexistent it was abandoned as too haz-
•j
ardous.-^
Little more was done with antibiotics until the somewhat
chance discovery of penicillin, by Alexander Fleming in 1928.
This penicillin proved to be a germicide many times more power¬
ful- than pyocyanase, which was the earlier antibiotic. This was
the first antibiotic to be produced in quantity and the real
^Ibid., p. 21.
2
Charles Pfizer and Go., Our Smallest Servants - The Story
of Fermentation (Brooklyn, 195^)» P* 7*
^Ibid.
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beginning of the wonder drugs.
Since antibiotics are the result of micro-organisms, then
the first step that must be taken before the antibiotic process
can be started is to find an efficient antibiotic strain. This
means finding a strain of micro-organisms capable of producing
an effective, relatively nontoxic antibiotic substance in com¬
mercial quantities.^ Effective strains of micro-organisms for
production of antibiotic medicines must be searched out, and
after thay are found, they must be preserved. In order to find
these useful micro-organisms, a large number of widely sampled
soils, grain, and foodstuffs are screened, and cultures are se¬
lectively Isolated. From among the selected cultures a few supe¬
rior producing micro-organisms are chosen.
A practical example of the way that this is done is through
the discovery by the Charles Pfizer Company of Terramycin in 19^1-9
Since it was necessary to assemble samples of as many types of
earth as possible, they obtained soil from graveyards, gold mines
mountain tops as well as dust from South America and mud from
swamps in Africa. After five years work and the collection and
testing of more than 100,000 soil samples the desired micro¬
organism was discovered and was found to be effective against
more than a hundred diseases (penicillin works against about
:^FTC Report, p. 111.
^John Gunther, Inside Pfizer (Brooklyn, 1957)» P» 6.
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twenty-five)
Production of antibiotics has increased rapldlyt about
1300 per cent, between the years 194-8 1958, the last year
for which accurate production figures were available* The
table shows the extent of the change*
TABLE 1
OUTPUT OP LEADING ANTIBIOTICS AND PER CENT'











Penicillins 155,873 64.. 9 1,059,604. 34.*4-
Streptomycin 80,737 33.6 14.8,999 5.8
Dlhydrostreptomyein 2,989 1.2 492.173 ,16.0
Chlorotetracycllne 661 .3 560,663 18*2
Oxytetracycline — 324,514 10.5
Tetracycline 220,074- 7*1
Chloromphenicol 4.6 (b) 85,4-08 2.8
Erythromycin 0 70,913 2*3
All others 26 (b) . 118,625 3.9
Total 24-0,332 100.0 3,081,373 100.0
®Taken from Pederal Trade Commission Antibiotics Report,
P. 67*
bLess than 0*1 per cent*
Table 1 shows that of the nine classifications, almost one
half of them in 1956 enjoyed production in excess of the total
output of the antibiotics manufactured in 194-8f the year of the
^Charles Pfizer and Co., Science Por The World*s Well
Being (Brooklyn, 1958), p. 2.
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introduction of the first broad spaetrum antibiotic.
A very substantial portion of th® world’s antibiotic out¬
put is produced in the nineteen antibiotics manufacturing plants
which operated in nine states. These nineteen plants, repre¬
senting twelve manufacturers are the stable antibiotics indus¬
try. During the period immediately following World War II the
Industry was in a state of flux, duo to the entry in the market
of such diverse, ”outsido** producers as Commercial Solvents,
Sohenley Laboratories and Glldden, which had an upsetting effect
on the industry.^ Those ”outoido” producers which were lured
into the industry by the clarion call of high profits during
the peak of the penicillin boom, have withdrawn, licking their
wounds, after the bottom dropped out of the penicillin market
and virtually eliminated any profits. The industry is now
thought to be quite stable and, although competition is quite
fierce within the Industry, there is no longer penetration in
this quite specialized business by outsiders.^
A further deterrent to outsiders entering into the indus¬
try is the huge initial expenditure for plant and equipment.
A typical plant constructed for the purpose of manufacturing
(but not packaging) one antibiotic plant was erected at a coat
of seven million dollars.3
^Carl M. Loeb, Rhodes and Go., The Ethical Drug Industry
and Four Leading Companies (New York, 1957)* P» 9*
^Ibid.
3
Federal Trade Commission Report, p. 102.
18
Present day plants must be elaborately equipped with automatic
devices to Insure sterility, to test and measure each process;
to agitate, cool and ventilate the antibiotics mixture; and
finally to filter, dry and store each gram of antibiotic in a
completely sterile environment*
The elaborate precautionary measures, necessary to Insure
sterility and purity, must be taken because there Is no room
for human error In the production of drugs. The slightest ru“
mor (whether or not true) can have a disastrous effect on the
earnings of a company. Ample evidence of this Is furnished by
the calamitous experience of Parke-Davls Company with Its broad
spectrum antibiotic, Chloromycetin, Introduced In 19i;-9» this
wonder drug achieved a dramatic growth in sales of from nine
million dollars In its first year to $52,000,000 In 1951*^ In
June of 1952 reports of several deaths supposedly resulting
from Chloromycetin received widespread publicity. A thorough
Investigation by the Food and Drug Administration cleared the
antibacterial compoxind of any direct casual relationship but
the damage had been done. The medical panic caused a preclpl-
tlous drop in Park-Davis’ sales. Within a few months sales of
of Chloromycetin In this country and Canada dropped from about
one million dollars per week to $100,000.^ The panic abated
and the drug Is staging a comeback but If It Is assumed, some¬
what conservatively, that sales would have remained stable at
^Carl M. Loeb., op. clt., p, 16.
^"Drugs on the Market," New York Times, March 22, 1958»p.23.
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at the 1951 level* (actually It la more reasonable to assume
a continuing upward trend) then the ’’panic” coat Parke-Davis
approximately #57*000,000 in sales over a three year period.
It is not difficult to imagine what would have happened to
the company, financially, if it could have been shown that human
error was indeed responsible for the deaths.
In addition to the huge capital outlays necessary for the
plant and equipment alluded the above, provision must be made
for huge fermentation installations, and for burial or other
disposal of thousands of gallons of wastematerial.^ Provision
must also be made for great amounts of power, heat, filtered
air and refrigeration and an immense supply of water. Chemi¬
cals of an explosive nature must be safely stored and often
large numbers of animals are maintained at the manufacturing
site for use in connection with pharmacological testing of anti¬
biotics products.^
This difficulty, then, for new producers to enter the field
is a good characteristic of the Industry and exerts a somewhat
stabilizing influence. A stable Industry is one of the prere¬
quisites of a situation eonduslve to long term investment in¬
terest.
1
Although yield varies with the type of antibiotic and is
a. very closely guarded company secret, a very rough idea of
the waste problem can be obtained from the fact that one com¬
pany reported an ’’average yield” of one pound of antibiotic per
280 gallons of broth.
2
Federal Trade Commission Report, p. 102.
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Marketing
Since the pharmaceutical Industry la so fiercely competi¬
tive and the nximber of products that are actually new that can
be Introduced Is limited, the problem'of marketing Is. more ex¬
actly a problem of selling, more so than In many other Indus¬
tries. The fact of the matter Is that the preservation of the
strong profit position of a particular manufacturer within the
Industry Is dependent on his creating In the mind of the con¬
sumer a preference for hla products, based on Imagined (In many
cases) rather than real differences.
Fifteen years ago, the pharmacist, surrounded by his elix¬
irs, compounded 75 per cent of the prescriptions ordered by doc¬
tors for patients but today nine out of ten prescriptions call
for a drug already prepared by a manufacturer.^ Formerly writ¬
ten In Latin the prescription now tends to be written In brand
names. When your druggist ask you to wait fifteen minutes while
ha "prepares” your prescription, the chances are that he Is on¬
ly trying to Impress you because* as It has been stated, "how
long does It take to write a label and transfer some capsules
from a larger bottle to a small ono?"2 it might be worth-while
to note that even though 90 P®r cent of the medicines are al¬
ready prepared, the prices to the consumer are as high and varied
as specially prepared prescriptions. One drug company’s specl-
^Mllton Moskowltz, "Wonder Profits In Wonder Drugs," The




alty, which cost a maximum of was recently priced with
1200 pharmacists across the country. Almost one-third were
overpriced, with some druggists charging more for thirty tab¬
lets than they paid for a whole bottle of one hundred. Prices
ranged from #1.76 in Ohio, to #5*l5 in Illinois.^
At the marketing level, the most important segment of the
antibiotics market as a whole is the doctor loyalty market be¬
cause this is the market in which ethical drug houses necessar¬
ily operate. This market is considered rather inelastic with
O
respect to price. The consumption of medicinal antibiotics
is controlled fundamentally by the Incidence of infections for
which they offer effective treatment and by prevailing medical
practice. Each antibiotic competes primarily with other anti¬
biotics. The physician selects the one which he regards as the
most effective in treating the illnesses rather than on the
basis of price, therefore the patient exercises no effective
choice.^
Promotion.—Since ethical drugs cannot be promoted to the
ultimate consumer, the sales pressure is therefore applied to
the doctor. The ethical pharmaceutical Industry today spends
between #250,000,000 and #300,000,000 annually on ’^professional”
advertising and various forms of sales promotions and the di¬
rect-mail techniques to doctors have reached tremendous propor-
Harold B. Jacobson, ’’The Truth About Prescription Prices,”
American Mercury. June, 1957, P» 23.
2
Federal Trade Commission Report, p. 67.
^Ibld.
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tlons. The general practitioner in New York receives close
to 5»000 copies of direct-mail a year*^ Perhaps the most im¬
portant form of advertising is done by the ’’detail men” whose
job it is to call on the members of the medical profession and
explain the characteristics of each new pharmaceutical marketed.^
From one company alone (Parke-Davis and Company) more than two
million calls on physicians throughout the country were made by
3
sales representatives or detail men in 1958.
Although in the pharmaceutical manufacturing industry one
dollar out of every five received from sales goes into promo¬
tional expenses (a figure unmatched by any other Industry) the
significance of this can be understood through cognisance of
the degree of competition which each pharmaceutical manufactur¬
er faces in his promotional program. Today, approximately seven
out of ten prescriptions filled by pharmacists are for drugs to¬
tally unknown prior to World War II. More amazing, perhaps, is
the finding that in July, 1957» more than six per cent of the
total drug store pharmaceutical volume was accounted by products
Introduced since the first of that year alone.^
■1
Harold B. Jacobson, op. cit.. p, 23»
2
The origin of the term, detail man, is obscure. In Europe
he is known as a medical visitor. The term has persisted in this
country despite all efforts to substitute a more accurate term
such as professional service representative.
l-iDavis & Co., Annual Report, 1958, p. 7*
Health News Institute, op. cit., p. 6l
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It Is not difficult to see the reason for the existence
of what has been described as ”hlgh pressure” salesmanship
and other aggressive marketing techniques. In the early days
of the Industry, a pharmaceutical manufacturer that produced
a new antibiotic was richly rewarded by an enormous market,
relatively free (or completely so) of competition and the ma¬
jority of the bigger firms were developers or co-developers
of Important antibiotics. Recently as the number of effec¬
tive drugs have Increased, It has become harder to discover
agents whose properties are really unique or bettor than those
already available. This, then, loads to the Intense competi¬
tion among manufacturers of existing preparations.
The Industry is then faced with the problem of how to
stimulate sales. This is accomplished mainly in three ways:
by making minor alterations in the chemical structure of an
antibiotic, by mixing two or more antibiotics together (some¬
times with a sulfa drug as well), or by mixing antibiotics
with headache remedies, vitamin pills and/or other non-antl-
blotlc medloinais. As a result, the six basic antibiotics -
the penicillins, streptomycins, tetracyclines,.chloromphenlcol,
erythromycin, and novobiocin - now appear on the market under
the labels of different manufacturers as approximately three
hundred different dosages or preparations.^
.
Vernon Knight, "Antibiotics: Too Much of a Good Thing
Harpers Magazine, February, 1958* P* 50.
2
Austin Smith and Arthxir D. Herrick, Drug Research and
Development (New York, 19^4-8), p. 4.85.
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Samples.—Of all the advertising media directed to the
medical profession, perhaps the moat effective is the sample.
The president of one of the largest pharmaceutical houses once
said that if his firm were required to give up, one after an¬
other, its three major types of advertising to the medical
profession, he would choose to abandon medical Journal adver¬
tising first. Second to be dropped would be direct mail. Last
to be given up would be the samples.^ The order of his choice
indicates, inversely, the order in which the three media usually
produce direct, traceable, dollars and cents results.
The ethical drug manufacturers discovered long ago that
there is a sort of sales magic in samples. It is thought that
in this field, probably more than any other, the power of sam¬
ples to make sales is proved. Even though, in many instances,
the sample may be far too small to observe its effect on even
one patient the fact that the physician has seen, handled, tast¬
ed or smelled the product may do more than any other type of
advertisement to register the name of the product and its uses
p
in the prospect's mind.
The extent to which some of the larger companies cultivate
the market through the use of the sample medium at times borders
on the incredible. Perhaps one of the most outstanding promo¬
tional efforts in the annals of the pharmaceutical industry was
that of American Cyanlmid in 19if8 in Introducing Aureomycin. When




of samples eere mailed to about li|.2,000 physicians. It has
been estimated that the cost of the product along was about
two million dollars.^
Research and Development
Reseach.ia, obviously, the key to the development of
drugs and a completely necessaary prerequisite for a company
to enjoy a prolonged upward trend in earnings and to maintain
a strong market position. Research is what gives the indus¬
try its continuing growth and without a sound and adequate re¬
search program, which gives a constant flow of new products,
the individual company will iiuickly find itself a ”has-beon”
in the profits race. In no other industry does the develop¬
ment of a new product, as the result of research, have the
sudden and dramatic impact on earnings as In the pharmaceutical
industry.
There have been few authoritative surveys of the drug in¬
dustry. A recent one, however, was made by David L. Babson
and Company, Investment Counselors, of Boston, Massachusetts.
The study made the telling point how a major discovery can
have a powerful impact on the.earnings of a company. The table
bn the following page shows the effect on sales and earnings,
within two years, after the introduction of a new product.
This dramatically illustrates the potential increase in the
John D. McEvllla, "Competition in the American Pharmaceu¬
tical Industry," Ph.D. thesis. University of Pittsburgh, 1957*
p. li|.3» quoted in Federal Trade Commission.
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stockholders equity that can, and does* accrue as the result
of one discovery.
TABLE 2
THE EFFECT ON SALES AND EARNINGS WITHIN TWO YEARS
AFTER THE INTRODUCTION OF A NEW PRODUCT*







Charles Pfizer - Antibiotic 1949 110 132
Smith, Kline & French - For
treatment of mental disturb¬
ances
1951}. 100 220
Sobering - Treatment for
arthritis
1955 320 850
Carter Laboratories - Treat¬
ment for mental dlat\irbance3
1955 200 5l5
Parke-Davls Co. - Antibiotic 1949 86 220
Taken from ”Drug Producers Look to Future,” New York Times.
February l5» 1959* Section III, p. 1.
If the data given in the table are examined more closely,
that is, if one of the entries is broken down into absolute
amounts, the point that is being made can be seen more clearly.
In 19i^-9» sales of the Charles Pfiser Company were $ij.7»000,000.
The latter part of the year they discovered the highly promising
antibiotic, Torramycln, and sales leaped to #60,000,000 in 1950
and to #100,000,000 in 1951Of course, not every dollar of
Charles Pfizer & Co., Inc., Annual Report, 1958, p. 18.
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of the Increase In sales can be attributed to the one product*
Terramycln, but It is recognized that a very large percentage
was due to its introduction on the market*
Today the producers of the ethical drugs race furiously
aith one another to bring out new products. The large phar¬
maceutical companies employ from five hundred to one thousand
research scientists. For example, the above mentioned Charles
Pfizer Company has over 750 research personnel, of whom 1^0
hold graduate degrees.^
Whereas the average cost of research in manufacturing in¬
dustries is 1 per cent of sales, in the pharmaceutical indus¬
try the average is 5 per cent.^ Smith, Kline and French, one
of the major producers of pharmaceuticals, recently announced
that it would spend $12,000,000 for research in 1959* ei'
crease of $1,000,000 over 1958* The significant aspect of this
is that profits in 1958 were $21,000,000 so this representative
company ploughs back approximately 57 per cent of profits into
research, more than any other industry.^
Before the war, ethical drug manufacturers employed only
a few researchers, relying on Europe and the universities for
basic research. In today's very competitive market, however,
manufacturers simply cannot wait around for a university selen-*
tlst to come up with an idea. The sales struggle has thus stlm-
1
Merrill Lynch, Pierce, Fenner and Beane, A Report of Pfizer
(New York, 1958), p. 5-
2
Milton Moskowitz, op. cit., p. 357*
^"More for Drug Studies,” New York Times, February4, 1959»P«5l
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ulated baalo research In pharmaceuticals. The prominence of
research and Its Impact can be Illustrated by the fact that
In 1958* more than one-half of the sales of one of the lead¬
ing producers (Scherlng Corporation) represented products that
have come from their laboratories In the past five years.^
This constant stream of nee products, which constantly
emanates from the laboratories then provide the means by which
the pharmaceutical Industry survives and prospers. It Is the
contention of the writer that this provides the opportunity
for both short and long-run gains, perhaps more than In any
other Industry^ It would be unfair and Inaccurate at this
point, not to point out that this very characteristic of hav¬
ing a steady flow of new products can have a deleterious effect
on the earnings of a particular company. This occ\ara when the
company Is unfortunate enough to have Its product line tied
too closely to one product or one particular type of product.
It la for this reason that the Individual firms within the In¬
dustry to ultimately, be In a worse position, through this rapid
r' ■
product obsolescence.
Not all chemicals are drugs but all drugs are. In a manner
of speaking, chemicals and for comparative purposes, many manu¬
facturing and research characteristics of the chemical Industry
apply to the pharmaceutical Industry. One of the more Important
characteristics which they share Is an extremely high rate of
obsolescence. It must be pointed out that in some branches of
1
Scherlng Corporation, Annual Report, 1958» P* 10.
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the industry it is customary to alloe only two to three years
for the expected life of the equipment*^ Accompanying this,
of course, is product obsolescence which is of more primary
consideration and which more directly affects the potential
earnings of a particular firm within the industry.
The generating force of the ethical drug business appears
to be a crash program of planned obsolescence. As we know, it
is the goal of the consumer goods manufacturers to create sales
by making his product appear obsolete but ”not even General
Motors has been able to achieve the rapid-fire product turnover
that prevails today in the pharmaceutical industry.Because
of the heavy investment in research, products can be, and are,
often outdated in a matter of months. When a company intro¬
duces a new product, it is safe to asstune that it is already
working to develop an important change or improvement. If the
company isn’t working on an improvement, its competitors are
doing so.^ Thus a manufacturer which markets a wide lino of
pharmaceuticals finds himself in a sort of juggling game with
his volximes shifting erratically from one product to another,
depending among other things on what happens to be,popular at
the moment.
Perhaps in no other industry is the Schumpeterian concept
of innovation profits more readily dlscornable than the drug
_
E. B. Alderfer and H. E. Michl, Economics of American
Industry (New York, 19^0), p. 256.
2
Milton Moskowltz, op. clt., p. 358.
^Ibld.
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industry. Being first with a new product is of prime impor¬
tance in this kind of market. Since a new product has no
guarantee of long life (and by the very nature of the market
seems more assured of a short life) the manufacturer is under
pressure to recover costa and make a profit in the period im¬
mediately following the introduction of a new product, when
prices are high. The manufacturer will enjoy a kind of innova¬
tion profit until the introduction of an improved product de¬
creases or eliminates the profits. Unless a maker gets in fast
makes a profit with a new product and keeps on finding newer
profits, he soon loses out.
Research, then, provides the peg upon which hangs the prof
it potential (and present profits) of the industry. The tre¬
mendous amounts of research expenditures serve to strengthen
and solidify the Industry and make justifiable the almost uni¬
versal optimism which pervades any discussion or study of the
industry.
The following chapter will relate these activities to se¬
curity prices within the industry and compare profit margins
with other industries.
1
Time Magazine. August 11, 1958* P» 68.
CHAPTER III
SECURITY VALUES WITHIN THE INDUSTRY
Todajy perhaps no subject Is so widely discussed as the
stock market. A nationwide rush to do business In the moat
exhuberant bull market since the 1920s has pushed volume on
the New York Stock Exchange to a series of successive highs,
which have reached, in some months, 75*000,000 shares and
above. This suggests that the United States Is reaching a
new era of economic growth.
There are In this country over nine million people who
own shares In publicly owned companies whose stocks are bought
and sold in the auction market, and their number Increases by
approximately 500,000 every year.^ Two-thirds of these people
have Incomes of $7500 per year, or less, but the ctirrent mar¬
ket value of their holdings total some $350,000,000 and nearly
90 per cent of these equities are locked away in strong boxes
and are not for sale.
The fact that such a huge amount of stock Is being held,
and not traded. Is significant because of the implication that
this reflects confidence in the economy as a whole. More spe¬
cifically, this would seem to indicate that these millions of
1
^Behind the Stock Market Turmoil,” Saturday Evening Post.





individuals are greatly optimistic (to the extent of $300*000»000)
that the economy will continue to grow; that their holdings will
continue to appreciate in value, and that they are going to be
the recipients of large dividends and stock splits. These are
quite likely to occur in an ascending market.
Industry growth prospects.—For investment program purposes
a growth stock may be defined as ”a common equity which after
a thorough analysis appears to have good possibilities of show¬
ing a significant long-term appreciation in market price.
An exact definition of a growth Industry is difficult to give
and few authors attempt to define such an industry. However,
leading characteristics to be noted are: (1) successive peaks
in sales and earnings each higher than the preceding peak; (2)
substantial sums spent on research and leadership in the devel¬
opment of new lines and products; (3) expansion of profits fast¬
er than that of the rate of population and possibly the move¬
ment of the general price level.^
A growth industry then is an industry which exhibits a
sustained upward trend in earnings through both good times and
periods of economic adversity. The list that follows is Fortune’s
summation of a variety of measurements applied by some of Wall
Street’s top growth stock specialists: (1) The company should
have had at least a three year history of growth, otherwise the
^Douglas A. Hayes, Appraisal and Management of Securities
(New York, 1956), p. 350.
David F. Jordan and Herbert E. Dougall, Investments (Engle¬
wood Cliffs, N. J., 1956), p.
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Investment may be in a cyclical situation or completely specu¬
lative. (2) Although growth companies can be found in mature
Industries, they are usually found in growth Industries, i.e.,
industries that are growing at a faster rate than the national
economy and appear to be capable of sustaining such growth.
(3) Over good and bad years for United States business as a
whole, a growth company's earnings should increase at-a rate
of at least 8 to 10 per cent a year. In the face of a general
business downturn, the company's earnings should be stable.
(i|.) The closer to the consumer a company's products are the
better. (5) If it hasn't paid any dividends, there should be
an indication that it will pay them in two or three years.^
The drug industry probably is somewhat unique in the mat¬
ter of growth. It is perhaps one of the few Industries where
it would Indeed be difficult not to find a company that fits
enough of the measurements to be called a growth situation.
Many Industries have been called, often haphazardly, growth in
dustrles but in the case of the drug industry the well-worn
appellation seems to be quite accurate.
Earnings trends of the industry.—One of the main charac¬
teristics of a growth Industry is its earnings trends. Follow
Ing is a table exhibiting net Income figures for the past ten
years for three random-chosen drug producers out of the first
ten ranked in net income, for 19^8. It was not possible to
William B. Harris, "Those Delicious Growth Stocks,”
,Fortune, April, 1959* P» 2^2.
secure strictly comparable data for all of the major producers
for the same period of time. It is thought, however, that these
companies are somewhat representative of the industry as a whole
TABLE 3
NET INCOME FOR THREE LEADING DRUG PRODUCERS
FOR THE TEN YEAR PERIOD 19ij.9 - 1958 (000 OMITTED
Abbott Laboratories Parke-Davis Chas* Pfizer
1958 12,873 28,041 23,965
1957 12,691 27,930 22,909
1956 10,589 17,547 18,254
1955 9,683 14,322 15,327
1954 8,702 10,494 15,201
1953 9,220 9,344 14,160
1952 8,846 16,256 10,663
1951 10,361 19,054 12,276
1950 10,880 17,865 9,941
1949 10,011 12,412 7,845
Data taken from various Annual Reports of the respective
companies.
The table indicates that the ethical drug Industry has
shown considerable growth over the past decade, profit-wise. Al¬
though it must bo admitted that advances have not been, during
the ten year period, continuously and steadily upward the alight
dips in earnings in 1953 and 195i|-» for some companies, have been
offset by new highs in sales upon emergence from the downturn.
Although this was true for some individual firms, the em¬
phasis of this study lies in the industry as a whole. Data
compiled for eight leading drug firms show that beginning in
19i|-7 there has been an increase each year over the previous year
35
with the exception of one year (1951) and then the decrease was
only 1.6 per cent.^ It la doubtful whether any other industry
can boast of an increase in sales for each successive year for
a period of some twelve years, with the exception of one year.
Of significance to this study is the fact that these data
seem to Indicate industry is practically depression proof. The
ethical drug business, which contributes so Importantly to hu¬
man health and comfort, la much leas subject to overall economic
2
fluctuations than most other industries. This is, of course,
a prime prerequisite for a growth industry or any other indus¬
try in which one desires to invest for the long pull. The years
1953-54 and 1957-^58 were years of recession with business ac¬
tivity depressed along practically all of the economic front.
During the years 1953-54» however, the eight leading drug manu¬
facturers showed combined increases, over the previous years, of
2.7 per cent in 1953 and 2.0 per cent in 1954*^ year 1958
was also a year of business recession, with business as a whole
being down approximately l4 per cent. Nevertheless, comparative
sales figures of the nineteen largest drug producers, for the
years 1957 and 1958 show that of the nineteen producers, seven¬
teen had an increase in sales despite the recession.^





^he Financial Pulse of the Drug Industry,” Financial World,
April 22, 1959, P. 5.
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It is not difficult to see why the industry is relatively
depression proof. In times of recession, when the consumer must
curtail various expenditures, medical services will be among
the very last to be cut. It was also noted in Chapter II, that
drugs are inelastic with regard to price since the physician
merely prescribes for the patient what is, in his opinion, the
most effective drug for the condition Irregardless of price.
Industry profits.—It is hardly a secret that the phar¬
maceutical industry enjoys substantial profits. In this sec¬
tion an attempt will be made to show that the drug industry
enjoys a profit advantage over many other industries. Even
though sales trends are significant and of utmost importance
it may be possible that increased sales could be accompanied by
offsetting Increases in expenses thereby achieving no actual im¬
provement in the position of the company and no increase in the
stockholder’s equity. Sales volume alone does not assure a fa¬
vorable level of earnings which are the ultimate factor in
choosing an attractive company or industry. It is for reasons
of this nature that attention must be focused on profit margins
and net Income in order to substantiate the premise that the
drug Industry is a growth industry and that the securities of
the industry, based on earnings projections and present trends
and ideal growth investments.
The following table illustrates the net income position
of the drug industry in relation to 378 industrial companies.
Also, averages for the seven year period have been computed to
compare the dr\ig3 with the Industrials over that period of time.
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TABLE Ij.
COMPARATIVE NET INCOME (MILLIONS OP DOLLARS) OF ELEVEN LEADING
DRUG COMPANIES AND 378 INDUSTRIAL COMPANIES COMBINED^^
(l9i^.7-l9l^-9- 100)









Data taken from Standard and Poor’s Industry Analysis,
1958, p. D-20*
On this comparative basis the drug industry clearly out¬
strips the rest of the industrial field. It must be admitted,
however, that seven years may not constitute a complete cycle
on which an industry can be analyzed. It is felt by the writer,
that the period under consideration contains enough high and low
levels of economic activity to establish a trend.
It was shown how net income of the drug industry compared
with 378 industrials combined. At this point it might be in¬
teresting to note just how the drug Industry compares with some
specific industries. The table that follows shows average oper-
ting income as a percentage of net sales for some selected in-
TABLE 5
AVERAGE OPERATING INCOME AS A PERCENTAGE OP NET SALES OP SOME SELECTED INDUSTRIES POR THE
lEARS 1950 - 1957^'^




Poods Furniture Liquor Steel Textiles
1957 24.17 - 14.67 9.46 7.46 11.40 19,56 20.95 6.97
1956 26.24 6.54 12.53 10.32 7.10 10.87 18.62 20.04 8.25
1955 22.24 7.10 17.70 12.18 9.58 9.77 18.60 13.61 8.86
133k 20.16 7.62 13.16 12.84 7.84 9.47 17.22 18.47 7.93
1933 20.16 6.92 13.50 12.50 7.56 9.40 18.62 18.62 10.01
1952 19.16 6.50 15.10 15.30 8.54 9.77 19.86 20,89 7.10
1951 27.51 7.28 14.77 17.02 5.16 12.50 25.80 18.71 12.17








23.30 6.99 15.05 13.59 8.11 10.95 20.76 18.75 9-55
Computations made from data contained in Standard & Poor’s Industry Surveys. I958.
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duatrles.^ The selected Industries cover a tilde and divergent
range of business endeavor. This clearly Illustrates how the
profit margins of the drug Industry compare with those of some
Industries of prime Investment calibre as well as some which
are generally considered as growth Industries.
It Is readily apparent then that not only are profit mar¬
gins In the pharmaceutical Industry larger than for other In¬
dustries as a whole but are far ahead of some of the most stable
highly ranked. Industries. It should be emphasized, at this
point, that the Industries appearing In Table 5 for comparative
purposes were selected completely at random. By this Is meant
that the selected industries were chosen only to give a cross-
section of manufacturing but without any previous knowledge or
preconceived notion whatsoever of what profit margins were with¬
in the respective Industries. Despite the arbitrary selection
It Is seen that of the eight Industries chosen and for the eight
year period, only on two occasions, the steel Industry In 1952
and the liquor industry in 1950, did any industry show a profit
margin greater than that of the drug industry*
Profit margins for the industry, which have not been as low
as 20 per cent since 1952, have shown a steady increase. This
steady Increase has been In spite of rising research and develop
1
Operating Income, as used In this study. Is the balance
left from sales after deducting operating costs, selling, gen¬
eral and administrative expenses, local and state taxes, pro¬
visions for bad debts and pension; but before other income and
before deducting depreciation charges, debt service charges.
Federal taxes, and any special reserves.
ment costs and over-all increases in operating expenses. This
can be explained by the fact that a large number of new, high
profit, patented compounds are introduced each year which, in
addition to providing large profit margins, sometimes replace
lower-priced nonpatented products. This, of course, raises
the average profit level of the entire line of goods. Last
year alone, for example, the drug manufacturers came up with
some four hundred now pharmaceuticals.^ This plethora of new
products explains in part why in 19^8, a recession year, the
industry sot sales records and sustained extremely high profit
levels.
Following la a table which illustrates the wide differen¬
tial between antibiotics manufacturers and the rest of the in¬
dustries with regard to the ratio between profits and assets.
The apparent disparity between the new profit figures in the
previous table and Table 6 is due to the fact that new profits,
in this instance, are computed as a percentage of assets and
not sales.
We see then that, by any criterion followed, the drug in¬
dustry stands far above all other manufacturing industries,
profit-wise. It will be noted that in 1952, the year of the
smallest differential, the antibiotics industry was yet l^..!
percentage points above all other industries, a not insignifi¬
cant amount. Also noteworthy is the fact that in 1951 and 1956
^”Drug on the Market,” New York Times, March 22, 1958, p. 28.
the antibiotics manufacturer’s profit margins were approxi¬
mately double that of the other industries.
TABLE 6
PERCENTAGE OP NET PROFITS BEFORE FEDERAL TAXES TO ASSETS OP













Taken from Federal Trade Commission Report on Antibiot¬
ics Manufacturers, p. 223.
Technically speaking, some adjustment of the profits fig¬
ures would have to be made to reflect more accurately the com¬
parative position of the pharmaceutical industry. This is be¬
cause some few pharmaceutical manufacturers are not antibiotics
manufacturers. Since the number of these firms is very
small, it is believed that the data approximate closely the
profit ratio between the pharmaceutical industry and other in¬
dustries.
Drug Securities.—Like the common stocks of many other
industries, the stocks of the pharmaceutical manvifacturers have
shown spectacular gains over a period of time. Whether they are
presently priced too high and whether or not they should contin¬
ue to hold the interest of the long-term investor are the ques-
4^
tlons that an attempt will be made to answer.
By any standard which may be applied the drug Industry has
performed well and especially Is this true of the past year.
The industry was ranked among the six best acting stock groups
and Is continuing to outpace the market, as a whole, in 1959*^
The performance of the Industry during the 1957-58 recession
clearly points out both the defensive and growth characteristics
of the group.Despite sharp price advances, valuation does
not appear excessive when compared with other growth industries.3
Since the drug stocks have been among the best performers
in the stock market and are easily outstepping the industrial
averages, many people are wondering whether they can keep it up.
The argiunent advanced here is that the stocks will still move
ahead of the market and command investor interest because of the
defensive traits that lead them to be considered as ’’depression
proof” , equities.
The rise of prices of drug stocks have been nothing less
than sensational. In 1957* for example, Parke-Davla had a low
of #42*37. Presently even after a three-for-one split in Novem¬
ber, 1958, it is selling at approximately #40*00* Without the
split this would indicate a present price of about #120.00 or
almost a 200 per cent increase in two years.
^’’Fiirther Growth Ahead for Drug Industry,” Financial World.
April 22, 1959* P* 5*
2
Standard and Poor’s, Industry Surveys, April 23» 1959»P*I5“2.
^Ibld.
This is not a hand-picked or isolated case. To cite another
example, Pfizer sold at #42.75 in 1957 and it reached a high
of #131.00 in 1959*^
Growth stocks invariably seem to be high priced for they
always sell at far higher price-earnings ratios than high grade
cyclical stocks. When the cyclical stocks, e.g., metals or
autos, are selling at ten times earnings, the growth stock will
sell at fifteen to twenty-five times earnings or more. Some
2
sell at such astronomical ratios as fifty times earnings.
The reason for this is as follows: theoretically a stock
is worth the present value of its future earnings. The analyst
who attempts to use the present value approach to growth stocks
will try to estimate dividends and earnings over a period of
time, say five years or so. Prom this ho tries to estimate the
price of the stock at the end of this time. Since the dollar
of the future is not worth a dollar today ho must discoxint the
future selling price and dividends at a rate he would like to
have on his Investment* Thus, simply put, he arrives at ’’pres¬
ent worth” of the stock. The high price-earnings ratios for the
drug stocks and any other growth stock is due to the market dis¬
counting a very high forecast earnings rate.
Historically, drug stocks sell at about twelve times earn-
JLngs. Some analysts feel that they should be upgraded - that
Harris, Upham & Co., Science and Securities (New York, May,
1959), P. 12.
2
William B. Harris, op. cit., p. 256.
they should sell at seventeen or twenty times earnings. Appar¬
ently the market agrees with the analysts because an inspection
of current prices will reveal that drug stock prices are rang¬
ing from nineteen to forty-five times 19^8 earnings. Even the
most conservative investors, wary of a decline in the market,
still lean toward drugs. They expect the drugs not only to
stay ahead of the market for the short term but think that the
equities hold good long term rewards.^
The increased investor recognition being given drug stocks
has been in a large measure, due to cognizance by the market of
two factors; research and exports. Since research has been dis¬
cussed, to a great extent, elsewhere in this study, only exports
will be mentioned at this point.
The recent surge of drug stocks to the forefront of market
performance is, of course, due to expectations of spectacular
gains in earnings. No small part of this is due to foreign sale
In fact foreign sales for some companies are growing at a faster
rate than domestic sales. The significance of the foreign mar¬
ket on earnings can be ascertained from the fact that in 1958,
Chas. Pfizer for example, had 39 Pei* cent of its sales accounted
for by its International Division.^
In England particularly has the market become an American





Chas. Pfizer & Co., Annual Report, 1958, p. 17*
market, as far as drugs are concerned. There are some twenty-
five subsidiaries of United States companies in Great Britian.
American firms have completely dominated the British antibiot¬
ics and tranquilizer market and supply an estimated one-half
of all the ethical drugs prescribed by the coxxntry’s physicians A
Performance of securities.—Although evaluation of an in¬
dustry necessitates an evaluation of sources and trends of earn¬
ings, we are interested in the behaviour and facts surrounding
its stocks. The following table shows some statistics regard¬
ing the stocks of the major companies of the industry.
These data reveal the sky-rocketing changes in the volues
of fo\irteen drug stocks that have taken place in the years 19^2-
59• Some of these increases have bordered on the fantastic. It •
will be noted that one stock (on an adjusted basis) increased
in value over ninety times during the period. The poorest per¬
former of the lot had an increase of only 66 2/3 per cent dur¬
ing the period.
The price-earnings ratios range from nineteen to forty-
four which is far above the custc^mary Industry average of around
fourteen. It is the opinion of the writer that in today’s mar¬
ket these do not appear to bo too oxceaslve. Many companies in¬
cluding some ”bluo-chips” are selling at from forty to fifty
times earnings.
The yield range is from 1.2 to 3*1 per cent, which appears
to be rather low, for comparative purposes, a look at yield
^"Gentlemen’s Business." Fortune , May, 1959» P»
TABLE 7









ilKh Low (Apr. 15.59)
Abbott Lab. CVJ 9^4 7k 22 2.6
Allied Lab. 59 3578 60 23 2.0
American Home
Products L3ii- 152 28 2.5
Bristol Myers 78 15 96 22 2.5
Carter Products !^3l 19 55 20 1.5
Merck & Co. 8334 9 8k 33 1.7
Parke-Davis 45 24 2.9
Pfizer, Chas. 37 115 26 2.0
Sobering Corp. 81% 5^4 61 20 2.0
Smith, Kline
French 36^4 133 31 2 • 2
Sterling Drug Sk 10I4 48 20 3.1
U, S. Vitamin 33^4 3 42 44 1.4
Vick Chemical 97 12 134 27 1.2
Warner-Lambert 1^884 7"4 104 19 2.9
Data from Financial World - Independent Appraisals of
Listed Stocka« June 3> 1959» and ’’Further Growth Ahead for
Drug Industry,” Financial World, April 22, 1959» P» 5*
averages for ten high-grade industrials, from 1951 through
1957» shows a range of from 3«96 per cent in 1952 to P®^
cent in 1957*^ To put the series on a more comparable basis,
the average yields of four high grade drug stocks were obtained
for the same series of years (1951 through 1957)• The drug
stocks had an average yield range of from 3.86 per cent in 1952
to 4.I4.8 per cent in 1953* Thus the drug stocks placed on the
same basis had almost identical yields with high grade indus¬
trials. In 1959* however, yields of drug stocks dropped con¬
siderably, only one of fourteen stocks having a yield greater
than 3 per cent. We then have the situation of industrial yields
advancing while drug yields are declining. This is due to the
fact that drug prices have outpaced the industrials and divi¬
dend payments have not kept pace with the appreciation in value
of the stocks, thereby causing a declining yield.
At first glance it might seem that this present character¬
istic of low yield would be an undesirable trait* As paradoxi¬
cal as it may seem, one of the most eminent authorities in the
investment field, Gerald M. Loeb, of E. P. Hutton & Go., saysi
”Stocks that yield the lowest return in dividends are generally
the beat buy. This is the reverse of what the amateur may
think but it is true nevertheless. A low return la very often
a sign that a company has put aside ample cash for research,
development and growth. Companies of this type usually have the
best management and good management is well-known as a key to
future profits.”2
^Moody’s Industrials, 1958» P* a22.
^Gerald M. Loeb, "Wise Insider Tells How to Make Money,”
Life, May.il, 1959» P» 26.
It might be said then that drug stocks, because of (not
in spite of) present low yields, are a good Investment medium
over the long run. For as one authority put it: ’’The larger
the dividend as a percentage of the selling price, the greater
the risk."!
Louis Engel, How to Buy Stocks (New York, 19^7), p. 80.
CHAPTER IV
LONG TERM GROWTH PROSPECTS OP THE INDUSTRY
In tho preceding chapter the past and the present perform¬
ances of the pharmaceutical industry were discussed. By al¬
most any standard of measurement the Industry has been a ster¬
ling performer. Tho questions now are: What are the long-term
growth prospects of the Industry? Where does it go from here?
It is thoughtby the writer that it would be difficult, if not
impossible, to find a single pessimist concerning tho future
of the industry.
The following reasons have been advanced for the oxhuber-
ance which is almost unanimously demonstrated for the industry:
1. There are large areas of disease yet to bo conquered.
2. The increasing population.
3. People are living longer.
i|.. Expanding foreign markets.
b. The ethical drug business has been leas subject to
economic fluctuations. ^
These reasons will bo examined in turn, with the exception
of the last which has been discussed in Chapter III, some other
factors which will have some bearing on the future.prospects
for the industry's earnings potential.
Unconquered disease.—Perhaps the greatest single factor
in the forecast long-term growth prospects of the pharmaceutical
^"Industry's Future Continue Bright," Journal of the Ameri¬
can Pharmaceutical Association, XIX (December, 195S), 731.
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industry is the fact that there are so many unoonquered dis¬
eases remaining. Step by step the medical scientists are
apparently approaching major breakthrough toward control and
cure of this country's three most costly diseases--heart ail¬
ments, cancer, and mental illness.^ In addition to these cost¬
ly diseases there also remains the common cold which has so far,
defied the research efforts of the industry. This is expected
to be resolved before the end of 1959* Parke-Davis & Co. hopes
to market a "common cold" Vaccine before the end of the year.^
Of tremendous consequence to the industry is the fact that
drugs are thought to be on the way to the conquest of cancer.
Drugs are already "sniping" successfully at some forms of hu¬
man cancer and in five to ten years these chemical "bullets"
should be stopping some types of cancer, regularly.^ In time
drugs should become the main defense against this disease. The
first of the new anti-cancer drugs may soon be put into the bat¬
tle against cancer. There are now at least ten new chemical
compounds being put through full clinical studies in humans
as treatments for various types of cancer.4-
Cancer which is the second largest cause of non-violent
deaths in the United States, is now being fought mainly by
^Alton L. Blakeslee, "Where Do We Stand on Cancer, Heart
Disease and Mental Illness," Today's Health, XXXVI (May, 1958),
p. l6.
2
"Parke-Davis Hopes to Market Vaccines for'Common Cold'' and
Measles this Year," Wall Street Journal, January 20, 1959, P* 3»
^Alton S. Blakeslee, op. cit., p. I7.
^"New-Ant1-Cancer Drugs Soon May be Ready for Use," Wall
Street Journal, April 3, 1959, P* 2I4..
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surgery and radiation.^ Although there is now no known drug
effective against cancer, every major chemical and pharmaceu¬
tical company is taking part in a vast screening program to
2
discover an effective agent. Considerable attention, how-r
over, has been recently given to the role of anti-biotics as
an agent for combatting cancer. Mitomycin C, developed in
Japan, and still in the experimental stage has been found effec¬
tive against certain forms of cancer.^
Of perhaps equal importance in the forecasts for the fu¬
ture of the industry is its fight against heart disease. The
problem of heart disease is complex, encompassing a score or
more cardiovascular maladies. For the most part, the industry
has not been able to achieve many real cures. Since cardio¬
vascular maladies, in 1957, accounted for 53 P©r cent of the
total deaths from all diseases, many in the industry believe
that the conquering ofheart disease offers the brightest poten¬
tial for the industry in the next decade.^ Thus, cancer and
heart disease offer the Industry virtually untapped areas for
growth and development.
Along with the above mentioned unconquered areas of dis¬
ease, the growth and development of the industry may be further
1
Standard & Poor's Industry Surveys, December I8, 1958, p.D-?.
^Ibid.
3




enhanced through newer developments In existing treatments.
Chief among these are improvements in present methods of com¬
batting polio.
An analysis of recent profit figures of the various drug
manufacturing companies would, in all probability, show that a
great part of their earnings growth was due to the introduction
of the polio vaccine. At the present time, however, a cheaper,
simpler, more effective vaccine is on the way which should have
dramatic Impact on the earnings in the Industry. Dr. Hilary
Kaprowskl, Director of the famed Wlstar Institute at the Uni¬
versity of Pennsylvania, has formulated an oral vaccine which,
if approved, is expected to replace the Salk vaccine.
Recently, American Cyanimld unveiled this cherry-flavored
oral vaccine and is now awaiting the authorization to begin pro¬
duction. With the contemplated one-dose preventive for polio,
it is not difficult to imagine the Improvement of earnings in
the industry that will possibly accrue.
A final, unconquered area of vast potential is in the area
of mental disorders. The scientists who probe the mind have
assisted in the development of a tremendous array of new drugs
which have virtually unlimited possibilities in the treatment
of mental disorders. Just as intriguing however, are the pos¬
sibilities inherent in the dr\igs which may sharpen the thinking
ability of the normal person.
The mental drugs first soared into prominence with the in¬
troduction of tranquilizers around 195^*^ Although the tran-
i
"Probing the Mind," Wall Street Journal, March 5» 1959,P*l»
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qulllzora are practically a household word and used by about
20 million persons, they do not appear to help the severely
depressed individual or the extremely apathetic. The search
by the drug makers then is for nee products to handle this
side of mental disease. ’’The big aim of pharmaceutical com¬
panies now is to find nee antidepressant drugs. That's ehere
1
the next big money drug eill be,” says a research psychologist.
Underscoring the importance being attached to this vast
development potential is the fact that a hospital in Port-au-
Prince, Haiti, has been opened for the treatment of the mentally
ill through drug therapy. This hospital, financed by three
United States pharmaceutical companiess Sobering Corporation,
Hoffman-LaRoohe, and Wyeth International, along with the Haitian
government, will attempt to discover whether multi-million dol-
2
lar mental hospitals are necessary. If these experiments are
successful the entire system of treatments for mental illnesses
will be revolutionized and the drug industry can soar to un¬
dreamed of highs, on the strength of this alone.
Population trends and lonRevity.—Accompanying the more
obvious possibilities for growth of the industry, e.g., the un¬
conquered diseases, and the necessity for introducing new anti¬




Some ofare what may bo called ’’built-in growth factors.”
these built-in growth factors are: (1) an increasing popu¬
lation that is believed to be becoming more health conscious
and (2) the expansion of the life of the Individual.
It is a well-known fact that the population of the United
States is rapidly Increasing. The projections for the next two
decades are these: 1959 “ 176 million; 198O - 2^0 million; and
2000 - 350 million.^ This tremendously expanding population la
one of the main reasons for the optimism which abounds concern¬
ing the future of the drug industry. Since 1950 the population
2
of the United States has swelled by about 25 million persons.
The meaning of this is clear. This portends a greatly expand¬
ing consumer market in the years immediately ahead. It would
seem to indicate that the economy of the United States la dy¬
namic and that many industries will grow with it. The evidence
indicates, to the writer, that the pharmaceutical industry will
be one of the primary beneficiaries of this rapidly expanding
market.
Of particular significance is the fact that the popula¬
tion is steadly growing older. Medical advances have greatly
increased the life expectancy of the population, opening up
vast new fields in drugs for the aged. The following table
illustrates how the expectation of life at birth in the United
^”The Male Decline,” Atlanta Constitution. May 20, 1959»
p. 1.
2..
’’Census Clock Keeping Count on Nation’s Expanding Markets,
New York Times, January 12, 1959» p. i|-l.
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States has Increased over the past fifty-six years*
TABLE 8
EXPECTATION OF LIFE AT BIRTH IN THE UNITED STATES (ALL RACES)*
Year Male Female Both Sexes
1900 5-6.3 5-8.3 5-7.3
1910 5-6*5- 51.8 50.0
1920 53.6 A.6 55-.1
1930 58.1 61,6 59.7
195-0 60.8 65.2 62.9
1950 65.7 71.3 68.2




^Source: National Office of Vital Statistics, U. S.
Department of Health, Education, and Welfare, quoted in In¬
stitute of Life Insurance, Life Insurance Pact Book (New York,
1958), p. D-8.
It is seen that during the fifty-six year period, covered
in the table, the life expectancy of the American people has
increased 22.3. years* Since these data were available only
through 1956, it la quite probable that the expectancy is now
above seventy years. Projections by the United States Chamber
of Commerce indicate that by 1970, 3*2 per cent of the total
population will be seventy-five years old or.over.and Q»l% per
cent will be sixty-five years old or over.^ Continuous re¬
search in the field of geriatrics would seem to Indicate that
there is a completely new area of drug manufacturing being opened.
Standard & Poor's , op. cit. (December 18, 1958), p. D-8.
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Another aspect of the ’’built-in growth factor” of popula¬
tion is the increase in the number of doctors in the United
States. Since ethical drugs are sold only through doctors, a
substantial increase in the number of physicians in the coun¬
try potentially provides for a substantial factor in the mar¬
ket for drugs.
According to the American Medical Directory, 1958 (page 13)»
there were 228,295 physicians in the United States at the time
of the most recent A.M.A. census during the spring of 1957*
This, however, includes 11,237 doctors who were retired or not
in practice.1 This number is expected to increase to about
235*900 8y i960. The projections presented provide for about
360 additional graduates each year between 196I and 1965. Con¬
tinuance of this ratio to 1975 requires substantial annual in¬
creases through the balance of the period until the number grad¬
uating reaches 12,14.90. This goal, if attained and consistently
sustained throughout the period, would provide about 325*200
physicians in 1975* Although it was not possible to obtain an
average number of prescriptions written per physician,, it is not
difficult to anticipate the volume of prescription specialties
practicing in Just sixteen years from now.
i
Letter from Leonard W. Martin, Ph.D. (Assistant Director,
Economic Research Department, American Medical Association,
May 27, 1959).
2George St. J, Perrott and Mayland Y, Pennell, ’’Physicians
in the United States: Projections 1955-75*" Journal of the
National Medical Association, L (November, 1958), p. 4.74*
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Expansion of foreign markets.—In the years Immediately
following World War II growth of drug exports was at a sharp
rate. Recently, however, with the return of European manu¬
facturers to the world market the Increase In United States
pharmaceutical exports has slowed somewhat.^ Some contribu¬
tory factors In the decrease In exports have been the dollar
shortage In some countries, difficulties In shipping some ma¬
terials long distances and tariff barriers. In this type of
situation. It Is apparent that the competitive advantage goes
to the company which has productive facilities on the spot.
As a result of this the establishment of foreign manufacturing
facilities la expanding. Exchange restrictions have apparently
served to accentuate the need for Investment of funds abroad.
It la expected that this trend will continue, even If ex-
2
change restrictions are removed. Lower labor and transporta¬
tion costs are among the factors which make this field attrac¬
tive to American Investors. Also, rising scales of living In
many foreign co\mtrlos and the need to upgrade sanitation and
health standards would seem to Indicate a growing foreign mar-
"ket for pharmaceutleal products In the years ahead.
Anti-trust action.—Of possible adverse effect on earnings
of some 1ndlyldual - companies and. In an Indirect manner, on the
earnings of the Industry as a whole are the anti-trust charges
pending against six companies of the Industry. These charges
^Standard & Foor's',? op. clt.. p. D-9.
^Ibld.
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by the Federal Trade Commission, climaxing a two year investi¬
gation of the industry, accuse the companies of price-fixing
and monopoly in the manufacture and sale of the antibiotic,
tetracycline. The significance of the pending charges lie in
the fact that the teracyclines represented almost 25 per cent
of the total antibiotics sales of the Industry in 1956 and is
probably higher at this time.^ According to Complaint Number
7211, United States of America before the Federal Trade Com¬
mission, the six companies account for 100 per cent of the sales
of this product, hence the monopoly charges.
It is not thought, however, that a ruling unfavorable to
the companies will have a significantly deleterious effect on
earnings of the eorapanlea in the long-run. The immediate, short
run, effect would possibly be unfavorable publicity for the in¬
dustry and greater division of the tetracycline market which may
or may not, decrease total Industry earnings.
Miscellaneous growth areas.—In addition to previously
mentioned elements of growth potential for the industry there
are other factors which can have spectacular effects on earn¬
ings in the future. Some of them will be discussed in the fpl-
lowlng paragraphs. They are in the areas of oral contraceptive
development and synthetic production of antibiotics.
Perhaps all major drug companies are pushing research to¬
ward the development of an oral contraceptive. Presently tests
are being conducted in Puerto Rico and Japan. The drawback in-
^Federal Trade Commission, op. cit., p. 2^6.
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volved la that the companies are not sure what the long-range
effects of the drugs will be. The first company that is able
to announce that it has perfected the completely safe drug will,
in all probability, reap a large harvest of innovation profits.
The second named area is that of synthetic production of
antibiotics* -The antibiotics field may be headed for an entire¬
ly new growth phase in the near future in view of some recent
research breakthroughs in the production of antibiotics by syn¬
thetic means.
The idea of making antibiotics synthetically la to produce
new wonder drugs that cannot be made by fermenting living organ¬
isms. Synthetic production will also enable the companies to
make improvements on existing drugs, eliminating certain draw¬
backs which may exist now. For example, synthetic production
may enable the industry to market a new type of penicillin which
would bo more effective against disease organisms but which would
eliminate the problem of allergic reactions to the antibiotic.
Synthetic production may decrease research expenditures con¬
siderably thereby freeing more funds for distribution to the
stockholders. This decrease in research expenditures could come
as the result of savings resulting from the discovery of a new
drug. Presently, the discovery of a new antibiotic results from
an examination of tens of thousands of soil samples from all over
the world. At that, the new antibiotic may or may not be superi¬
or to or different from those presently existing. It is hoped
that the production of antibiotics synthetically will eliminate
many of the Intermediate steps prior to the discovery and pro-
6o
ductlon of a new product. This could revolutionize the industry
and send it to new plateaus of economic activity. Theoretically
at least, the possibilities are unlimited.
Industry pro .lections.—Up to this point, the future pros¬
pects of the industry have been considered from a somewhat gener¬
al point of view. It might be asked at this juncture, what are
some specific projections for the industry? George B. Stone,
General Manager of J.B. Roerig Company (a subsidiary of Chas.
Pfizer) recently made some forecasts at the Central Region meet¬
ing of the Pharmaceutical Manufacturers Association in Chicago.
He sees fabulous long-term growth prospects for the indus¬
try in all major drug categories in the years ahead. Corticos¬
teroids, an $80,000,000 business in 19^6, are expected to in¬
crease by 112 per cent by 1965* Cardiovascular products are ex¬
pected to soar 198 per* cent by I965 from the $87,000,000 level
of 1956. Tranquilizers will, according to Stone, climb 13^1- per
cent and biologicals and vaccines, 2i|.3 per cent. Cancer drugs,
which are insignificant now, may become a $200,000,000 business
by 1970, he believes.^
In view of the fact that sales of ethical drugs increased
from$336 million in 194-5 to$1.7 billion in 1957, sales of ethi-
cals should exceed $2,000,000,000 by I96O. The multiplicity of
growth factors inherent in the industry would make even a casual
^’’Further Growth Ahead for Drug Industry,” Financial World,
April 22, 1959* P* 5»
^Ibid., p. 27.
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observer somewhat optimistic over the growth potential of the
pharmaceutical industry. If past performance can be considered
as a criterion for projecting performance of an industry then
the future is indeed rosy. The drug industry, however, is not
to be considered as a primrose path to certain riches. No in¬
vestment is certain. It is the opinion of the writer that,
comparatively speaking, the drug industry enjoys certain advan¬
tages over many other industries for long-term growth prospects.
The facts, as presented here, seem to support this contention.
CHAPTER V
SUIVIMARY AND CONCLUSIONS
Although the pharmaceutical industry is many years old,
the recent advent and subsequent mass production of the so-
called "wonder drugs" has transformed it into a completely new
industry. This revitalized industry had made a transition from
a quiet, orderly affair to one of the more fiercely competitive
industries in the economy. In a little more than a decade the
industry has come from a relatively obscure position, attract¬
ing little important investor Interest, to a 1)2,000,000,000
sales industry commanding a second look at its prospects.
The behaviour of the Industry suggests that it belongs to
that select group of industries to which has been attached the
appellation "growth industry." This label has often been ap-
plied, somewhat promiscuously, to a variety of industries by in¬
dividuals who are just cultivating an interest in the stock mar¬
ket. Today's nationwide interest in the stock market has created
a situation where a great number of investors are not Interested
In the high-yield stocks but are looking for the growth situation
that will appreciate in value. Although there is not unanimity
of opinion among authorities as to just what constitutes a growth
situation, it seems that the drug Industry meets most of the cri¬
teria that have been set forth by most.
The more than a decade of spectacular gains recorded by the
industry have been accompanied by an attendant rise in its secu-
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rity values. The problem confronting the potential investor is
determining whether or not these prices are out of proportion
to the potential earning power of the companies of the Industry,
Any purchaser of the so called "growth stocks" pays a rather
high price for them because he is, to a large extent, buying
potential rather than past performance. Does the drug Industry
have the potential which justifies foregoing present income in
anticipation of long-term capital appreciation? It is the opin¬
ion of the writer that an affirmative answer is justifiable and
that an observation of the facts about the industry substanti¬
ates this affirmative answer.
It is believed that the Industry today is on firm footing.
Early unsteadiness which was attributable to severe intra-indus¬
try competition, substantial overcapacity, price vulnerability
on certain items (e.g. penicillin) and industry penetration by
non-drug producers has been largely eliminated. The industry
has learned a lesson from the intense price competition in pehr
icillin, streptomycin and cortisone, and is now confining com¬
petition within the industry largely to research and merchandis¬
ing, Although the competition within the industry is still in¬
tense the nature of it has changed, prices have been stabilized,
and a multiplicity of new products with broad markets has emerged
from research.
The research factor is the life of the Industry and no other
Industry ploughs back as much of the earnings dollar into re¬
search as the drug industry. This highly competitive and costly
6k
research program provides the means whereby the Industry is able
to sustain profit margins that are higher than in practically
any other industry. This is because the constant flow of new
products which emanate from the laboratories represent great in¬
vestments in development costs. The manufacturer must recover
these costs and provide for profit margins before the product be¬
comes obsolete through the research of his competitors.
Reflecting the somewhat continuous upward trends in sales
and earnings is the record of drug stock performances during the
period between l^k^ s-^d 1959* The record of their price move¬
ments during this period shows that, on an adjusted basis, some
drug stocks have increased in value as much as seventy five times.
The classification of the drug industry as a growth industry
would seem to be a natural reaction when past records along with
growth potential are considered. Perhaps of paramount Importance
to the longterm investor is the growth potential of the industry.
Optimism abounds from practically every quarter concerning the
growth potential. This optimism which prevails throughout the
industry is predicated on the following reasons:
(1) The drug industry is growing faster than the economy.
(2) The population trend is continuously upward.
(3) The foreign market is expanding at an even greater rate
than the domestic market, in many instances,
(I4.) There are new applications of drug products for non¬
human uses such as animal health and health, plant
disease and industry.
(5) There is a constant development of new products from
research.
(6) There are a number of important diseases remaining to
be conquered.
(7) The drug business, because it contributes so importantly
to human health and comfort, is less subject to overall
economic fluctuations than most other industries.
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This series of factors tend to make drug shares, in the
opinion of the writer, attractive for investors who are desirous
of long-term capital appreciation. The possibility of dramatic
new -developments which cause earnings to soar within a short
period of tini-e is constantly present in the drug Industry, per¬
haps more than any other-industry is possibly the most attractive
of the growth industries may be disputed by the reader but if
past performance and logical projections are suitable criteria
then the Investor who selects the drug industry should do ex¬
tremely well over the next decade or longer.
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